Ironwood Pharmaceuticals and AstraZeneca PLC (AZN) Initiate Linaclotide Phase 3 Trial in China for Adults With IBS-C
9/10/2013 9:38:35 AM
CAMBRIDGE, Mass. & SHANGHAI--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and AstraZeneca Pharmaceuticals Co., Ltd. today announced the initiation in China of a Phase III clinical trial of linaclotide for the treatment of adults with irritable bowel syndrome with constipation (IBS-C). Linaclotide is currently approved in the United States for adults with IBS-C or chronic idiopathic constipation (CIC) and in the European Union for adults with moderate to severe IBS-C.
Help employers find you! Check out all the jobs and post your resume.